安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Amyloid-beta immunotherapy: the future for Alzheimer’s therapeutics . . .
Since the year 2003, when the Food and Drug Administration (FDA) approved Memantine, an N-methly-D-aspartate (NMDA) glutamate receptor antagonist, as its latest therapeutic for AD, 3 countless clinical trials have failed to effectively target and eliminate one of the fundamental pathologies in AD – amyloid-beta (Aβ) plaque
- Passive immunotherapy for Alzheimer’s disease: challenges future . . .
Passive immunotherapy with specific anti-Aβ antibodies has emerged as a promising therapeutic approach In a recent phase III clinical trial involving 1169 AD patients, Sperling et al evaluated the therapeutic effects of solanezumab, a monoclonal antibody (mAb) targeting monomeric Aβ peptide, with negative outcomes
- If amyloid drives Alzheimer disease, why have anti-amyloid . . . - PLOS
Then, we document how recent clinical trials targeting Aβ were certainly not a complete failure but rather resulted in lowering of amyloid plaque pathology in the brain and even reduced tau alteration and neurodegeneration, formally establishing disease modification
- Contribution of amyloid deposition from oligodendrocytes in a mouse . . .
While BACE1 inhibitors have been shown to reduce Aβ levels in people with AD, clinical trials targeting BACE1 have failed due to unwanted synaptic deficits Understanding the physiological role of BACE1 in individual cell types is essential for developing effective BACE inhibitors for the treatment of AD
- The amyloid hypothesis in Alzheimer disease: new insights from new . . .
With the aim of informing this debate, we review clinical trial data for drugs that target Aβ from the perspective of the temporal interplay between the two pathognomonic protein
- Phase II Trial of Anti-Amyloid AR1001 Signals Little Promise for . . .
AR1001 acts by inhibiting phosphodiesterase 5 protein, which is believed to have benefits against the accumulation of amyloid beta (Aβ) peptides, the main pathological hallmark of AD AR1001 showed potential evidence of promoting neuronal cell survival in AD during early stage studies
- Aducanumab in the treatment of Alzheimers disease | CIA
Over the last 25 years, several drugs targeting Aβ have failed to show clinical efficacy in trials, including five anti-Aβ antibodies: bapineuzumab, solanezumab, crenezumab, ponezumab, and gantenerumab 25, 26 Thus, supporters of the amyloid hypothesis placed high hopes on aducanumab
- Cover Page for ClinicalTrials
clinical trials targeting just one (often Aβ) of the neurotoxic aggregating proteins have failed Finally, other fragments of Amyloid β Precursor Protein (APP) have been implicated in AD pathology Collectively, these facts point to the need for development of combination therapies
|
|
|